Maintenance of response after open-label treatment with atomoxetine hydrochloride in international European and non-European adult outpatients with attention-deficit/hyperactivity disorder: A placebo-controlled, randomised withdrawal study

Himanshu Upadhyaya, J. Antoni Ramos-Quiroga, Lenard A. Adler, David Williams, Yoko Tanaka, Jeannine R. Lane, Rodrigo Escobar, Paula Trzepacz, Angelo Camporeale, Albert J. Allen

Research output: Contribution to journalArticleResearchpeer-review

20 Citations (Scopus)

Abstract

Background and Objectives: We evaluated maintenance of response to atomoxetine during a 25-week, double-blind, placebo-controlled, randomised withdrawal period in adults with attention-deficit/hyperactivity disorder (ADHD) who previously responded to atomoxetine during a 12 week open-label treatment period and maintained that response during a 12-week double-blind maintenance period. Methods: Patients (N = 2017), 18 to 50 years of age, diagnosed with ADHD from 152 outpatient sites in 18 countries received 12 weeks of open-label atomoxetine (40-100 mg/day) followed by 12 weeks of double-blind maintenance (80 or 100 mg/day). Responders were randomized to atomoxetine (N = 266) or placebo (N = 258) for 25-weeks of double-blind treatment. The percentage of patients with a reduction ≥30% in their baseline Conners' ADHD Rating Scale Investigator-Rated: Screening Version (CAARS-Inv:SV) total score and a score of ≤3 on the Clinical Global Impression ADHD-Severity (CGIADHD-S) after 25 weeks was compared between treatment groups with a Fisher's exact test. Mean changes from baseline in the CAARS-Inv:SV and Adult Attention-Deficit/Hyperactivity Disorder Quality of Life (AAQoL) were analysed. Results: Most patients enrolled (60%) were from Europe. More atomoxetine than placebo-treated patients maintained a satisfactory response postrandomisation (64.3% vs. 50.0%; p <.001). Time-to-relapse was significantly longer for atomoxetine than placebo (p =.004). Atomoxetine maintained greater improvements in ADHD symptoms compared with placebo (LS mean worsening in the CAARS-Inv:SV total score was 0.9 vs. 4.8 [p <.001] and in the CGI-ADHD-S rating was 0.0 vs. 0.5 [p <.001]). These results were supported by self-or ob-server-rated measures. Lastly, atomoxetine maintained greater improvements in quality of life compared with placebo (AAQoL total score was 0.4 vs. -4.0; p =.002). Conclusions: This study demonstrated that atomoxetine was superior to placebo in maintaining significantly greater treatment responses for up to 1 year in adults with ADHD.
Original languageEnglish
Pages (from-to)185-205
JournalEuropean Journal of Psychiatry
Volume27
Issue number3
DOIs
Publication statusPublished - 1 Jul 2013

Keywords

  • ADHD
  • Adult
  • Atomoxetine
  • Attention-deficit/hyperactivity disorder
  • European

Fingerprint Dive into the research topics of 'Maintenance of response after open-label treatment with atomoxetine hydrochloride in international European and non-European adult outpatients with attention-deficit/hyperactivity disorder: A placebo-controlled, randomised withdrawal study'. Together they form a unique fingerprint.

Cite this